摘要 |
Disclosed herein is a dosage form for administering a dose of 500mg scyllo-inositol to a subject, which are suitable for oral administration, for use in the prevention, treatments or control of symptoms of a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence, wherein the effective dose to be administered comprises scyllo-inositol in a dosage form selected from the group consisting of tablets, capsules, lozenges, gelcaps, buccal patches, suspensions, solutions, gels and drug matrix compositions to effect the sustained release of the scyllo-inositol and drug matrix compositions to effect the rapid release of scyllo-inositol.
|